Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec. - Suppr | 超能文献

Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec.

作者信息

Beri Nidhi, Kapoor Lekha, Parashar Deepak, Mundada Vivek

机构信息

Special Need Dentistry, Aster DM Healthcare, Dubai, UAE

ENT, Aster DM Healthcare, Dubai, UAE.

出版信息

Arch Dis Child. 2023 Oct;108(10):866-867. doi: 10.1136/archdischild-2023-325788. Epub 2023 Aug 8.

DOI:10.1136/archdischild-2023-325788

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec.

Arch Dis Child. 2023 Oct;108(10):866-867. doi: 10.1136/archdischild-2023-325788. Epub 2023 Aug 8.

2

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.针对 1 型脊髓性肌萎缩症（SMA）的婴儿期起病症状性的 Onasemnogene abeparvovec 基因治疗（STR1VE-EU）：一项开放标签、单臂、多中心、3 期临床试验。

Lancet Neurol. 2021 Oct;20(10):832-841. doi: 10.1016/S1474-4422(21)00251-9.

3

Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.在全球管理准入计划中，体重为 8.5 公斤或更重的脊髓性肌萎缩症患者使用 Onasemnogene Abeparvovec 的安全性。

Pediatr Neurol. 2022 Jul;132:27-32. doi: 10.1016/j.pediatrneurol.2022.05.001. Epub 2022 May 10.

4

Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.脊髓性肌萎缩症 Onasemnogene Abeparvovec 治疗后发生坏死性小肠结肠炎：病例系列。

J Pediatr. 2023 Sep;260:113493. doi: 10.1016/j.jpeds.2023.113493. Epub 2023 May 20.

5

Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.Onasemnogene abeparvovec 可维持脊髓性肌萎缩症前期婴儿的延髓功能：SPR1NT 试验的事后分析。

Neuromuscul Disord. 2023 Aug;33(8):670-676. doi: 10.1016/j.nmd.2023.06.005. Epub 2023 Jun 22.

6

Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.依洛硫酸酯酶 n 基因治疗脊髓性肌萎缩症的真实世界观察性研究。

Gene Ther. 2023 Aug;30(7-8):592-597. doi: 10.1038/s41434-022-00341-6. Epub 2022 May 24.

7

Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.儿童脊髓性肌萎缩症的基因治疗：单中心 25 例患儿队列的经验

Muscle Nerve. 2023 Sep;68(3):269-277. doi: 10.1002/mus.27926. Epub 2023 Jul 1.

8

Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio.俄亥俄州持续的onasemnogene abeparvovec 安全性和长期疗效。

Neuromuscul Disord. 2024 Jan;34:41-48. doi: 10.1016/j.nmd.2023.11.010. Epub 2023 Dec 2.

9

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.依洛硫酸酯酶 n 注射液治疗携带 2 个 SMN2 拷贝的脊髓性肌萎缩症婴儿起病型患者的症状：一项开放标签、单臂、多中心、3 期临床试验。

Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17.

10

Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis.onasemnogene abeparvovec基因治疗脊髓性肌萎缩症的安全性和有效性：一项系统评价和荟萃分析。

J Paediatr Child Health. 2023 Mar;59(3):431-438. doi: 10.1111/jpc.16340. Epub 2023 Feb 1.

引用本文的文献

1

A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders.用于单基因疾病的 AAV 基因治疗中使用的免疫抑制方案的系统评价。

Mol Ther. 2024 Oct 2;32(10):3220-3259. doi: 10.1016/j.ymthe.2024.07.016. Epub 2024 Jul 22.